|
|
News Breaks
|
January 5, 2012
|
| 08:38 EDT |  | SHPGY |
| theflyonthewall.com: | Shire's Venvanse marketing application accepted for review in Europe | | Shire plc announced the acceptance for review of their once-daily ADHD medicinal product Venvanse, or lisdexamfetamine dimesylate, by the Medicines Healthcare products Regulatory Agency, or MHRA, UK. The MHRA have agreed to act as the Reference Member State for this Decentralised Procedure, or DCP, which will initially include eight European countries.This application follows the successful completion of the European Phase 3 study of Venvanse in children and adolescents with Attention-Deficit/Hyperactivity Disorder, or ADHD, last year. :theflyonthewall.com |
|
|
News For SHPGY From The Last 14 Days Check below for free stories on SHPGY the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
